Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Ultragenyx Pharmaceutical Inc. (RARE) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Ultragenyx Pharmaceutical Inc. (RARE) lobbying for?
Summary:
Ultragenyx Pharmaceutical Inc. hired three lobbying firms to lobby on pharmacy and health issues, specifically on the Newborn Screening Saves Lives, SPEEDING Therapy Access Today (STAT) Act, Ensuring Lasting Smiles Act, HEART Act of 2020 – H.R. 7567, Reauthorization Act, Cures 2.0, Health and Human Services, H.R. 5376, reimbursement, and Related Agencies Appropriations Act (H.R.4502), S.3062), the Build Back Better Act, Orphan Drug Tax Credit, and market access, H.R. 482/ S. 350, Fairness in Orphan Drug Exclusivity Act S. 250, Senate Finance Committee Drug Pricing Principles and Issues related to rare disease. They lobbied on these issues in the Senate, Department of Health & Human Services (HHS), and House of Representatives over the 10 most recent lobbying contracts.
Inference:
One could infer that Ultragenyx Pharmaceutical Inc. is lobbying on these issues to promote its business interests as a pharmaceutical company. Specifically, the company is seeking to ensure market access and reimbursement for its pharmaceutical products, including orphan drugs meant to treat rare diseases. They are also advocating for new legislation that would make it easier for patients to access their drugs and advocating for the new newborn screening program to identify patients who could benefit from their products. Overall, lobbying on these issues can help Ultragenyx Pharmaceutical Inc. achieve its goal of increasing its revenue and improving its long-term profitability.
